Lexeo Therapeutics, Inc. Common Stock Lexeo Therapeutics, Inc. Common Stock

Lexeo Therapeutics, Inc. Common Stock

LXEO

Rank in Stocks #15555
Lexeo Therapeutics, Inc. is a genetic medicine firm currently in the clinical... Lexeo Therapeutics, Inc. is a genetic medicine firm currently in the clinical development phase, dedicated to addressing both inherited and acquired medical conditions. Its robust pipeline features several gene therapy candidates. These include LX2006, an AAVrh10-based therapy aimed at treating cardiomyopathy linked to Friedreich's ataxia (FA); LX2020, another AAVrh10-based candidate targeting arrhythmogenic cardiomyopathy; LX2021, designed for DSP cardiomyopathy; and LX2022, which focuses on hypertrophic cardiomyopathy (HCM) stemming from TNNI3 mutations. Furthermore, Lexeo is advancing LX1001, an AAVrh10-based gene therapy, alongside LX1020 and LX1021, all intended for individuals homozygous for APOE4. Additionally, LX1004 is under development to treat CLN2 Batten disease. Established in 2017, the company's headquarters are located in New York, New York.
Share Price
$2.87
Last synced: 2026-11-13
Market Cap
$245.75M
Change (1 day)
-1.37%
Change (1 year)
-68.32%
Country

Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this

Trade Lexeo Therapeutics, Inc. Common Stock (LXEO)

Category

Healthcare
EPS for Lexeo Therapeutics, Inc. Common Stock (LXEO)
EPS as of June 2026 TTM: $-1.15
According to Lexeo Therapeutics, Inc. Common Stock's latest financial reports, its current EPS (TTM) is $-1.15. At the end of 2025 the company had an EPS of $-1.86, an increase over its 2024 EPS of $-3.09.
EPS history for Lexeo Therapeutics, Inc. Common Stock from 2020 to 2026
EPS at the end of each year
Year EPS Change
2026 (TTM) $-1.15 -38.17%
2025 $-1.86 -39.81%
2024 $-3.09 24.10%
2023 $-2.49 5.51%
2022 $-2.36 17.41%
2021 $-2.01 905.00%
2020 $-0.20 0.00%
EPS for similar companies or competitors
Company EPS EPS Difference Country
$-0.89 -22.61%
US
$15.66 -1,461.74%
US
$-7.07 514.78%
US
$-5.29 360.00%
AU
$12.73 -1,207.15%
BE

Questions about Lexeo Therapeutics, Inc. Common Stock's earnings per share (EPS)

What is Lexeo Therapeutics, Inc. Common Stock's earnings per share (EPS)?

Lexeo Therapeutics, Inc. Common Stock's earnings per share (EPS) over the last twelve months is $-1.15, as of Jun 2026.

What was Lexeo Therapeutics, Inc. Common Stock's earnings per share (EPS) in 2025?

In 2025, Lexeo Therapeutics, Inc. Common Stock's earnings per share (EPS) was $-1.86, compared with $-3.09 in 2024.

How has Lexeo Therapeutics, Inc. Common Stock's earnings per share (EPS) changed since 2020?

From 2020 to 2025, Lexeo Therapeutics, Inc. Common Stock's earnings per share (EPS) was highest in 2020 ($-0.20) and lowest in 2024 ($-3.09).

How does Lexeo Therapeutics, Inc. Common Stock's earnings per share (EPS) compare with similar companies?

Lexeo Therapeutics, Inc. Common Stock's earnings per share (EPS) ($-1.15) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with $15.66.